GcMAF and Chronic Infections
Restoring macrophage-mediated pathogen clearance
Many chronic bacterial and viral infections — including Lyme disease, Epstein-Barr virus, chronic hepatitis, and HIV-associated immune deficiency — are associated with elevated nagalase levels, which suppress endogenous GcMAF production. By restoring macrophage activation through exogenous GcMAF, the immune system may regain its capacity to target and clear persistent pathogens.
Key Findings
- Nagalase elevation documented across multiple chronic viral and bacterial infections
- GcMAF shown to restore macrophage phagocytosis in vitro studies
- Clinical reports of improved outcomes in HIV-positive patients
- Research supports antiviral properties via macrophage and NK cell activation
Mechanism of Action
Activated macrophages serve as frontline defenders against persistent pathogens. GcMAF restores their capacity for phagocytosis, intracellular killing of pathogens, and co-ordination of broader adaptive immune responses that eliminate chronic infection reservoirs.
Clinical Notes
Use in chronic infections should involve identification and monitoring of nagalase levels as a biomarker. Treatment protocols should be designed by infectious disease specialists.
Interested in GcMAF for Your Clinic?
Contact our medical team to discuss clinical applications and procurement.
Next Application
Immune Enhancement